Live Breaking News & Updates on Genomics Solutions|Page 6
Stay updated with breaking news from Genomics solutions. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Prolific developments in life sciences, characterized by rapid AI penetration, industry-wide proliferation of cloud technology, and possible therapeutic connotations of previously contraband substances such as marijuana are amongst some key developments that have led to the emergence of a trillion dollar global phar. ....
Lab Automation Market Size to Reach Revenues of USD 8.58 Billion by 2026 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Share this article Share this article ResearchAndMarkets.com s offering. The author suggests that the global laboratory automation market is predicted to display growth at a CAGR of 5.14% over the assessed period 2021-2028. Factors such as better than non-automated laboratories, the advancement of laboratory systems, and the surge in R&D sectors, are majorly driving the progress of the studied market. Additionally, growth in investments in pharma and biotech companies and demand for high accuracy with less turnaround period, are factors generating multiple opportunities for the laboratory automation market. However, physical constraints, costly setup processes, and technology integration challenges negatively impact the market s future growth. ....
Press release content from Business Wire. The AP news staff was not involved in its creation. Agilent Receives Approval for GenetiSure Dx Postnatal Assay in Japan December 23, 2020 GMT SANTA CLARA, Calif. (BUSINESS WIRE) Dec 22, 2020 Agilent Technologies Inc. (NYSE: A) announced it has obtained clearance from the Ministry of Health, Labour and Welfare (MHLW) in Japan for the GenetiSure Dx Postnatal Assay – a microarray-based assay for diagnostic use. This assay enables clinical geneticists to detect genetic aberrations associated with developmental delay, intellectual disabilities, congenital anomalies, and unexplained dysmorphic features. The company also announced that it has registered its microarray scanner, SureScan Dx Scanner, as a Class I medical device in Japan, intended for use with the assay. ....